Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As previous studies showed that the synergy between linezolid and carbapenem in vitro and in vivo (animal studies), our study is aim to investigate the activity of linezolid, alone and in combination with carbapenem against methicillin-resistant Staphylococcus aureus (MRSA) in ventilator-associated pneumonia (VAP) patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin

NCT01561469

Methicillin-Resistant Staphylococcus Aureus (MRSA) Hospital-Acquired Pneumonia

COMPLETED

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

NCT00572559

Pneumonia, Ventilator-Associated

COMPLETED PHASE4

Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

NCT01819935

Pneumonia

COMPLETED

Cost Effectiveness Of Linezolid In Central America

NCT01040585

Ventilator Acquired Pneumonia

WITHDRAWN

The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

NCT00811980

Sepsis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Linezolid is the only commercially available oxazolidinone, the first new class of antibiotic to be developed in the last three decades. Although it is predominantly bacteriostatic, linezolid has good in vitro and in vivo activity against MRSA . However, several studies did not show that linezolid was superior to any of glycopeptides in treatment of MRSA pneumonia. Moreover, combination therapy against MRSA is argued when several in vitro and in vivo studies showed synergy between linezolid and carbapenem or fosfomycin or rifampicin, while vancomycin and linezolid in combination should be avoided. our study is aim to investigate the activity of linezolid, alone and in combination with carbapenem against methicillin-resistant Staphylococcus aureus (MRSA) in ventilator-associated pneumonia (VAP) patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Methicillin-resistant Staphylococcus Aureus Pneumonia, Ventilator-Associated

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Linezolid alone

the control group is designed for linezolid alone treated MRSA VAP (standard treatment).

Group Type NO_INTERVENTION

Imipenem/cilastatin

Intervention Type DRUG

the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imipenem/cilastatin

the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pneumonia, Ventilator-associated

* the presence of new or persistent radiographic features
* fever higher than 38°C
* leukocytosis (≥11.0 ×109/L) or neutropenia (≤3.5×109/L)
* purulent endotracheal
* increasing oxygen requirements
* Endotracheal aspiration culture show methicillin-resistant S. aureus positive

Exclusion Criteria

* immunocompromised patients (postorgan transplantation or human immunodeficiency virus-infected or neutropenic \[≤1×109/L absolute neutrophils\], or patients receiving corticosteroids \>20 mg/d for 6 months)
* colonized chronically with methicillin-resistant S. aureus
* pregnancy
* endotracheal aspiration culture showed no MRSA

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No